[Treatment of early threatened abortion (6th-16th week of pregnancy) using a new tocolytic agent (Th 1165a)].
D000033:Abortion, Threatened / Q000188:drug therapy*; D000438:Alcohols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D009921:Metaproterenol / Q000009:adverse effects / Q000627:therapeutic use*; D007752:Obstetric Labor, Premature / Q000517:prevention & control; D010636:Phenols / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000517:prevention & control; D011261:Pregnancy Trimester, First; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D013997:Time Factors; D014700:Verapamil / Q000627:therapeutic use
D000438:Alcohols; D010636:Phenols; D009921:Metaproterenol; D014700:Verapamil
Die Behandlung des drohendedn Frühabortus (6. bis 16. Schwangerschaftswoche) mit einem neuen Tokolytikum (Th 1165a)